業績

2020

Fujibayashi Y, Isa R, Nishiyama D, Sakamoto-Inada N, Kawasumi N, Yamaguchi J, Kuwahara-Ota S, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Handa H, Kuroda J. Aberrant BUB1 overexpression promotes mitotic segregation errors and chromosomal instability in multiple myeloma. Cancers, 12: 2206, 2020. （群馬大学血液内科との共同研究）

Kuwahara-Ota S, Shimura Y, Steinebach C, Isa R, Yamaguchi J, Nishiyama D, Fujibayashi Y, Takimoto-Shimomura T, Mizuno Y, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Kobayashi T, Horiike S, Taniwaki M, Gütschow M, Kuroda J. Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma. Br J Haematol, 191: 784-795, 2020.（独国　ボン大学との共同研究）

Nakaya A, Kohara T, Shibayama H, Onda Y, Kanda J, Kaneko H, Imada K, Kida T, Kosugi S, Ishikawa J, Yamamura R, Shimazu Y, Tanaka H, Fuchida SI, Shimura Y, Kiyota M, Wada K, Ito T, Uoshima N, Yagi H, Yoshihara S, Ohta K, Shimazaki C, Hino M, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S; Kansai Myeloma Forum Investigators. Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry. Int J Hematol, 12(4):435-438, 2020.（多施設共同研究）

Inaba T, Tsukamoto T, Fujita N, Kuroda J. Auer-bodies in cellular components other than typical myeloblasts. Int J Hematol, 112(5):605-606, 2020.（本学臨床検査医学との共同研究）

Kawaji-Kanayama Y, Nishimura A, Yasuda M, Sakiyama E, Shimura Y, Tsukamoto T, Kobayashi T, Mizutani S, Okamoto S, Ohmura G, Hirano S, Konishi E, Shibuya K, Kuroda J. Chronic invasive fungal rhinosinusitis with atypical clinical presentation in an immunocompromised patient. Infect Drug Resist, 13:3225-3232, 2020.（本学病院病理部との共同研究）

Kuwahara-Ota S, Shimura Y, Mizuno Y, Takimoto-Shimomura T, Matsumura-Kimoto Y, Tanba K, Tsukamoto T, Chinen Y, Mizutani S, Kobayashi T, Horiike S, Kuroda J. Impact of high serum lactate dehydrogenase in multiple myeloma in upfront autologous　stem cell transplantation in the era of new drugs: A single institute experience. Int J Myeloma, 10: 21-25, 2020.

Nakaya A, Tanaka H, Yagi H, Ohta K, Shibayama H, Kohara T, Kanda J, Shindo M, Shimura Y, Kosugi S, Kida T, Kaneko H, Imada K, Karasuno T, Matsuda H, Iida M, Adachi Y, Fuchida S, Uoshima N, Uchiyama H, Takahashi R, Matsui T, Wada K, Kiyota M, Shimazaki C, Hino M, Kuroda J, Kanakura Y, Takaoari-Kondo A, Nomura S, Matsumura I. Retrospective analysis of plasmacytoma in Kansai Myeloma Forum registry. Int J Hematol, 12(5):666-673, 2020.（多施設共同研究）

Chinen Y, Tanba K, Takagi R, Uchiyama H, Uoshima N, Shimura K, Fuchida S, Kiyota M, Nakao M, Kobayashi T, Shimura Y, Tsukamoto T, Horiike S, Wada K, Shimazaki C, Kaneko H, Kobayashi Y, Taniwaki M, Yokota I, Kuroda J, Kyoto Clinical Hematology Study Group Investigators. Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma. Leuk Lymphoma, 61: 3378-3386, 2020.（KOTOSG研究）

Shimura Y, Tsukamoto T, Yamaguchi J, Kuwahara-Ota S, Isa R, Nishiyama D, Kobayashi T, Horiike S, Suzuki A, Kuroda J. Towards further simplification of Elotuzumab therapy by subcutaneous administration. Int J Hematol, 112, 427-428, 2020.

Kagami Y, Yamamoto K, Shibata T, Tobinai K, Imaizumi Y, Uchida T, Shimada K, Minauchi K, Fukuhara N, Kobayashi H, Yamauchi N, Tsujimura H, Hangaishi A, Tominaga R, Suehiro Y, Yoshida S, Inoue Y, Suzuki S, Tokuhira M, Kusumoto S, Kuroda J, Yakushijin Y, Takamatsu Y, Kubota Y, Nosaka K, Morishima S, Nakamura S, Ogura M, Maruyama D, Hotta T, Morishima Y, Tsukasaki K, Nagai H. R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908study. Cancer Sci, 111(10):3770-9, 2020.（多施設共同研究）

Maruyama D, Terui Y, Yamamoto K, Fukuhara N, Choi I, Kuroda J, Ando K, Tobinai K. Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Jpn J Clin Oncol, 50(11):1265-1273, 2020.（多施設共同研究）

Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, Chinen Y, Tanba K, Kuwahara-Ota S, Fujibayashi Y, Nishiyama D, Isa R, Yamaguchi J, Kawaji-Kanayama Y, Kobayashi T, Horiike S, Taniwaki M, Kuroda J. Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma. Cancer Med, 9: 5185-5199, 2020.

Sakiyama E, Chinen Y, Tsukamoto T, Takimoto-Shimomura T, Kuwahara-Ota S, Matsumura-Kimoto Y, Shimura Y, Kobayashi T, Horiike S, Kuroda J. Tuberculous peritonitis during treatment of polycythemia vera with ruxolitinib. Infect Drug Resist, in print.

Chinen Y, Tsukamoto T, Maegawa S, Matsumura-Kimoto Y, Takimoto T, Tanba K, Mizuno Y, Fujibayashi Y, Ota S, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Kuroda J. Tumor-specific transcript variants of cyclin D1 in mantle cell lymphoma and multiple myeloma with chromosome 11q13 abnormalities. Exp Hematol, in print.

Isa R, Uoshima N, Takahashi R, Nakano-Akamatsu S, Kawata E, Kaneko H, Shimura K, Kamitsuji Y, Takimoto-Shimomura T, Mizutani S, Chinen Y, Ohshiro M, Fujino T, Kawaji Y, Uchiyama H, Sasaki N, Tsukamoto T, Shimura Y, Kobayashi T, Taniwaki M, Kuroda J, Kyoto Clinical Hematology Study Group investigators. Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma. Ann Hematol, 99:137-145, 2020.　（関連施設KOTOSGの共同研究）

Matsumoto Y, Chinen Y, Shimura Y, Nagoshi H, Sasaki N, Muramatsu A, Kuriyama K, Ohshiro M, Hirakawa Y, Iwai T, Uchiyama H, Taki T, Horiike S, Kuroda J, Taniwaki M. Recurrent intragenic exon rearrangements of SOBP and AUTS2 in non-Hodgkin B-cell lymphoma. Int J Hematol. 111: 75-83, 2020.（関連施設との共同研究）

Tsukamoto T, Nakahata S, Sato R, Kanai A, Nakano M, Chinen Y, Maegawa-Matsui S, Matsumura-Kimoto Y, Takimoto-Shimomura T, Mizuno Y, Kuwahara-Ota S, Kawaji Y, Taniwaki M, Inaba T, Tashiro K, Morishita K, Kuroda J. BRD4-regulated molecular targets in mantle cell lymphoma: insights into targeted therapeutic approach. Cancer Genomics Proteomics,17: 77-89, 2020.（広島大学、宮崎大学、本学ゲノム医科学教室との共同研究）

黒田純也. 多発性骨髄腫 Multiple myeloma. 今日の治療指針 volume 62. 2020年版. 医学書院. 704-707, 2020

黒田純也. IV. 1. 治療開始時期. 多発性骨髄腫の診断指針第5版. 文光堂 32-33, 2020.

黒田純也、山口順子. 多発性骨髄腫に対する二重特異性T細胞誘導抗体. 血液内科81(3), 354-358, 2020.

黒田純也、志村勇司. 多発性骨髄腫 multiple myeloma. 入門腫瘍内科学（改訂第3版）. 南江堂. 印刷中

下村（滝本）とも子、黒田純也. 再発・難治性の慢性リンパ性白血病に対する経口BCL-2阻害薬ベネトクラクスの有用性. 血液内科、印刷中.

黒田純也. 骨髄腫の診断および鑑別診断・病型分類・リスク分類　～多様な診断基準の相違点を論じる～ カレントテラピー、印刷中.

黒田純也、塚本　拓、志村勇司. 形質細胞性白血病の診断と治療　Diagnosis and treatment of primary plasma cell leukemia 日本臨牀増刊「造血器腫瘍学（第2版）」、印刷中

黒田純也、志村勇司. 再発・難治性多発性骨髄腫の治療ストラテジー. 癌と化学療法、印刷中.

黒田純也、塚本　拓. 急性骨髄性白血病に対するBCL2阻害剤 venetoclax. 日本臨床78(3), 514-520, 2020.

2019

Takimoto-Shimomura T, Shimura Y, Nagata K, Inaba T, Chinen Y, Tsukamoto T, Kobayashi T, Horiike S, Sotozono C, Kuroda J. Primary intraocular natural killer-cell lymphoma successfully treated using a multidisciplinary strategy. Ann Hematol, 98: 2617-2619, 2019.（本学眼科との共同研究）

Nagafuji K, Matsumura I, Shimose T, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Kadowaki N, Ishikawa J, Imamura Y, Yamazaki H, Akashi K, Kanakura Y. Cessation of Nilotinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Deep Molecular Responses for 2 Years. A Multicenter Phase 2 Trial, Stop Nilotinib (NILSt). Int J Hematol, 110:675-682, 2019. （多施設共同研究）

Sakaguchi M, Yamaguchi H, Kuboyama M, Najima Y, Usuki K, Ueki T, Oh I, Mori S, Kawata Uoshima N, Kobayashi Y, Kako S, Tajika K, Shono K, Kayamori K, Hagihara M, Kanda J, Uchiyama H, Kuroda J, Uchida N, Kubota Y, Kimura S, Kurosawa S, Date K, Nakajima N, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Wakita S, Arai K, Kitano T, Kakihana K, Kanda Y, Ohashi K, Fukuda T, Inokuchi I. Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia. Int J Hematol, 110:566-574, 2019.（多施設共同研究）

Asai J, Yamaguchi J, Tsukamoto T, Chinen Y, Shimura Y, Kobayashi T, Katoh N, Kuroda J. Treatment rationale and design of a phase II study of narrow-band ultraviolet B phototherapy for cutaneous steroid-refractory acute graft-versus-host disease following allogenic stem cell transplantation. Medicine, 98: p e16372, 2019（本学皮膚科との共同研究）

Yamaguchi J, Chinen Y, Takimoto-Shimomura T, Nagata H, Muramatsu A, Kuriyama K, Ohshiro M, Fujimoto Y, Iwai T, Uchiyama H, Uoshima N, Kaneko H, Nakao M, Tsukamoto T, Shimura Y, Kobayashi T, Horiike S, Yokota I, Kuroda J. Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma. Leuk Lymphoma, 60: 3434-3441, 2019.（関連施設KOTOSGの共同研究）

Fujimoto S, Sakai T, Kawabata H, Kurose N, Yamada S, Takai K, Aoki S, Kuroda J, Ide M, Setoguchi K, Tsukamoto N, Iwao-Kawanami H, Kawanami T, Mizuta S, Fukushima T, Masaki Y. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol, 94:975-983, 2019.（多施設共同研究）

Kawaji Y, Nagata H, Muramatsu A, Kuriyama K, Ohshiro M, Hirakawa Y, Iwai T, Kobayashi T, Uchiyama H, Urata Y, Kuroda J. Diffuse large B-cell lymphoma with chromosomal translocation t(14;19)(q32;q13) occurring in IgG4-related disease. Ann Hematol, in print.

Matsumoto Y, Kobayashi T, Shimura Y, Kawata E, Nagoshi H, Ohshiro M, Sugitani M, Shimura K, Iwai T, Fuchida S, Yoshida M, Kiyota M, Mizutani S, Chinen Y, Takimoto-Shimomura T, Nakao M, Kaneko H, Uchiyama H, Uoshima N, Nishigaki H, Kobayashi Y, Horiike S, Shimazaki C, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group. Combined chemotherapy of rituximab, bendamustine and dexamethasone for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: A multicenter phase II study. Int J Hematol, in print.

Yamaguchi J, Fujino T, Isa R, Nishiyama D, Kuwahara-Ota S, Tsukamoto T, Chinen Y, Shimura Y, Kobayashi T, Horiike S, Kohno K, Nakamura S, Kuroda J. Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia. Haematologica, in print.（名古屋大学臓器病態診断学との共同研究）

Mizuno Y, Chinen Y, Tsukamoto T, Takimoto-Shimomura T, Matsumura-Kimoto, Fujibayashi Y, Fujino T, Nishiyama D, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Kuroda J. A novel method of amplified fluorescent in situ hybridization for detection of chromosomal microdeletions in B cell lymphoma. Int J Hematol, in print.

Sasaki N, Shimura K, Yoshida M, Uoshima N, Kiyota M, Hatsuse M, Uchiyama H, Chinen Y, Kobayashi T, Nakao M, Takahashi R, Nakano-Akamatsu S, Kaneko H, Kobayashi Y, Shimazaki C, Taniwaki M, Kuroda J; The Kyoto Clinical Hematology Study Group (KOTOSG) investigators. Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patients. Int J Hematol, 109: 278-285, 2019. （京都府立医科大学生物統計学教室、血液内科と関連施設の共同研究）

Takamatsu H, Yamashita T, Kurahashi S, Saitoh T, Kondo T, Maeda T, Nakazawa H, Murata M, Narita T, Kuroda J, Hashimoto H, Kawamura K, Miyamoto T, Honda S, Ichinohe T, Atsuta Y, Sunami K. Clinical implications of t(11;14) in patients with multiple myeloma undergoing autologous stem cell transplantation. Biol Bone Marrow Transplant, 25:474-479, 2019. （多施設共同研究）

黒田純也. 多発性骨髄腫における遺伝子異常. 臨床検査 63(7), 832-837, 2019.

水野芳美、黒田純也. びまん性大細胞型B細胞性リンパ腫に対する免疫チェックポイント阻害薬. 血液内科 78(4),469-473, 2019.

黒田純也. 低悪性度B細胞性腫瘍に対する分子標的薬. 病理と臨床37(3)、233-237, 2019.

黒田純也. 多発性骨髄腫の診療 2018. 松仁会医学誌　58(1), 1-9, 2019.

2018

Watanabe T, Tobinai K, Wakabayashi M, Morishima Y, Kobayashi H, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Yoshino T, Nawano S, Terauchi T, Hotta T, Nagai H, Tsukasaki K; JCOG0203 Collaborators. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. Lancet Haematol, 5: e520-e531, 2018.（多施設共同研究）

Sakaguchi M, Yamaguchi H, Najima Y, Usuki K, Ueki T, Oh I, Mori S, Kawata E, Uoshima N, Kobayashi Y, Kako S, Tajika K, Gomi S, Shono K, Kayamori K, Hagihara M, Kanda J, Uchiyama H, Kuroda J, Uchida N, Kubota Y, Kimura S, Kurosawa S, Nakajima N, Marumo A, Omori I, Fujiwara Y, Yui S, Wakita S, Arai K, Kitano T, Kakihana K, Kanda Y, Ohashi K, Fukuda T, Inokuchi K. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Adv, 2: 2744-2754, 2018. （多施設共同研究）

Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Takahashi N, Abe M, Ishida T, Nagura E, Shimizu K. Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma. Hematol Oncol, 36: 792-800, 2018. （多施設共同研究）

Nakaya A, Yagi H, Kaneko H, Kosugi S, Kida T, Adachi Y, Shibayama H, Kohara T, Kamitsuji Y, Fuchida S, Uoshima N, Kawata E, Uchiyama H, Shimura Y, Takahashi T, Urase F, Ohta K, Hamada T, Miyamoto K, Kobayashi M, Shindo M, Tanaka H, Shimazaki C, Hino M, Kuroda J, Kanakura Y, Takaoari-Kondo A, Nomura S, Matsumura I, Kansai Myeloma Forum Investigators. Retrospective analysis of primary plasma cell leukemia in Kansai Myeloma Forum registry. Leuk Res Rep, 10: 7-10, 2018. （多施設共同研究）

Takimoto-Shimomura T, Tsukamoto T, Maegawa S, Fujibayashi Y, Matsumura-Kimoto Y, Mizuno Y, Chinen Y, Shimura Y, Mizutani S, Horiike S, Taniwaki M, Kobayashi T, Kuroda J. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. Invest New Drugs, in print.

Inoue Y, Nakamura T, Nakanishi H, Oishi M, Hongo F, Okihara K, Mizutani S, Kuroda J, Ukimura O. Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients. Int J Urol, 25: 678-683, 2018.（京都府立医科大学泌尿器科との共同研究）

Takimoto-Shimomura T, Nagoshi H, Maegawa S, Fujibayashi Y, Tsukamoto T, Mastumura-Kimoto Y, Mizuno Y, Chinen Y, Mizutani S, Shimura Y, Horiike S, Taniwaki M, Kobayashi T, Kuroda J. Establishment and Characteristics of a Novel Mantle Cell Lymphoma-derived Cell Line and a Bendamustine-resistant Subline. Cancer Genomics Proteomics, 15:213-223, 2018.

Yamasaki S, Chihara D, Kim SW, Izutsu K, Iwato K, Fukuda T, Uchida N, Amano I, Nakazawa H, Kuroda J, Hashimoto H, Ichinohe T, Kanda Y, Atsuta Y, Suzumiya J, Suzuki R. Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma. Ann Hematol, 97:1445-1452, 2018.

Kuwahara-Ota S, Chinen Y, Mizuno Y, Takimoto-Shimomura T, Matsumura-Kimoto Y, Tanba K, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, Horiike S, Kuroda J. Human herpesvirus-6 pneumonitis in a patient with follicular lymphoma following immunochemotherapy with rituximab. Infect Drug Resist, 11;701-705, 2018.

Iida S, Wakabayashi M, Tsukasaki K, Miyamoto K, Maruyama D, Yamamoto K, Takatsuka Y, Kusumoto S, Kuroda J, Ando K, Kikukawa Y, Masaki Y, Kobayashi M, Hanamura I, Asai H, Nagai H, Shimada K, Tsukamoto N, Inoue Y, Tobinai K. Bortezomib plus dexamethasone versus thalidomide plus dexamethasone for relapsed or refractory multiple myeloma. Cancer Sci, 109;1552-1561, 2018.

Kaneko H, Taniwaki M, Matsumoto Y, Yoshida M, Shimura K, Fujino T, Uchiyama H, Kuroda J. An adult-onset case of chronic active Epstein-Barr virus infection with fulminant clinical course. J Infect Chemother, 24;479-482, 2018.

Taniwaki M, Yoshida M, Matsumoto Y, Shimura K, Kuroda J, Kaneko H. Elotuzumab for the treatment of relapsed or refractory multiple myeloma, with special reference to its modes of action and SLAMF7 signaling. Mediterr J Hematol Infect Dis, 10:e2018014, 2018.

Ishikawa J, Matsumura I, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Matsuoka K, Shibayama H, Hino M, Hirase C, Kamimura T, Shimose T, Akashi K, Kanakura Y. Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: the results of multicenter phase II trial (NILSw trial). Int J Hematol, in print.（多施設共同研究）

Mizuno Y, Tsukamoto T, Kawata E, Uoshima N, Uchiyama H, Yokota I, Maegawa S, Takimoto T, Tanba K, Matsumura-Kimoto Y, Kuwahara-Ota S, Fujibayashi Y, Yamamoto-Sugitani M, Chinen Y, Shimura Y, Horiike S, Taniwaki M, Kobayashi T, Kuroda J. Chromosomal abnormality variation detected by G-banding is associated with prognosis of diffuse large B cell lymphoma treated by R-CHOP-based therapy. Cancer Med, in print. （京都府立医科大学生物統計学教室、血液内科と関連施設の共同研究）

Maegawa S, Chinen Y, Shimura Y, Tanba K, Takimoto T, Mizuno Y, Matsumura-Kimoto Y, Kuwahara-Ota S, Tsukamoto T, Kobayashi T, Horiike S, Taniwaki M, Kuroda J. Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma. Exp Hematol, in print.

Matsumura-Kimoto Y, Kuroda J, Kaneko H, Kamitsuji Y, Fuchida S, Nakaya A, Shibayama H, Uoshima N, Yokota I, Uchiyama H, Yagi H, Kosugi S, Matsui T, Ishikawa J, Matsuda M, Ohta K, Iida M, Tanaka H, Kobayashi M, Wada K, Shimazaki C, Nomura S, Imada K, Hino M, Matsumura I, Kanakura Y, Takaori-Kondo A, Kansai Myeloma Forum Investigators. Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum. Int J Hematol, in print.（多施設共同研究）

Tanba K, Chinen Y, Uchiyama H, Uoshima N, Shimura K, Fuchida S, Kiyota M, Nakao M, Shimura Y, Kobayashi T, Horiike S, Wada K, Shimazaki C, Kaneko H, Kobayashi Y, Taniwaki M, Kuroda J. Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma. Blood Cancer J, in print. （京都府立医科大学血液内科と関連施設の共同研究）

下村（滝本）とも子, 堀池重夫, 志村勇司, 知念良顕, 杉谷（山本）未央, 古林 勉, 黒田純也. 抗凝固剤内服中に発症した後天性血友病Aにおける診断の問題点. 日本輸血細胞治療学会誌 64(3), 540-544, 2018.

黒田純也. 多発性骨髄腫の診療 2018. 松仁会医学誌、印刷中

黒田純也. B細胞リンパ腫および骨髄腫に対するBCL2阻害剤venetoclaxの開発状況と今後の展開. 血液内科77(4)、451-456, 2018

古林　勉、黒田純也. 未治療びまん性大細胞型B細胞リンパ腫に対する治療強度を高めた治療戦略の位置づけと今後の課題. 血液内科、76(6), 738-744, 2018.

志村勇司、黒田純也. 骨髄腫の生存・増殖シグナル. 日本臨床、76(7), 1070-1086, 2018

清田実希、黒田純也. 濾胞性リンパ腫の治療.　最新医学別冊. 診断と治療のABC133. 悪性リンパ腫. 第4章. 管理・治療：治療薬剤. 2. 濾胞性リンパ腫の治療.126-133,2018.

清田実希、黒田純也. 濾胞性リンパ腫. クリニシアン 663(65), 153-162, 2018.

黒田純也. ホジキンリンパ腫 Hodgkin lymphoma. 今日の治療指針 vol.60 2018年版. 医学書院. 669, 2018.

2017

Tsukamoto T, Nakano M, Sato R, Adachi H, Kiyota M, Kawata E, Uoshima N, Yasukawa S, Chinen Y, Mizutani S, Shimura Y, Kobayashi T, Horiike S, Yanagisawa A, Taniwaki M, Tashiro K, Kuroda J. High-risk follicular lymphomas harbour more somatic mutations including those in the AID-motif. Sci Rep, 7; 14039, 2017.（本学ゲノム医科学教室、病院病理部、血液内科関連施設との共同研究）

Matsumoto Y, Nagoshi H, Yoshida M, Kato S, Kuroda J, Shimura K, Kaneko H, Horiike S, Nakamura S, Taniwaki M. Expression of Master Regulators of T-cell, Helper T-cell and Follicular Helper T-cell Differentiation in Angioimmunoblastic T-cell Lymphoma. Intern Med, 56:2851-2856, 2017. （京都府立医科大学血液内科と関連施設の共同研究）

Masuzawa N, Nishimura A, Kitani T, Tamagaki K, Sugitani M, Nagoshi H, Kuroda J, Konishi E. A case of the nephrotic syndrome in bone marrow transplantation recipient, histologically showing overlapped glomerular lesions of thrombotic microangiopathy and membranous nephropathy. Pathol Int, in print. （京都府立医科大学病院病理部との共同研究）

Matsuda K, Matsumoto Y, Yoshida M, Shimura K, Kaneko H, Inaba T, Horiike S, Kuroda J, Taniwaki M. Hairy B-cell lymphoproliferative disorder and its differential diagnosis: a case with long-term follow-up. Mediterr J Hematol Infect Dis, 9; e2017054, 2017.

Takimoto T, Kobayashi T, Tsukamoto T, Maegawa S, Tanba K, Matsumura-Kimoto Y, Mizuno Y, Kuwahara-Ohta S, Chinen Y, Mizutani S, Nagoshi H, Yamamoto-Sugitani M, Shimura Y, Horiike S, Fujita N, Kuroda J. High frequencies of drug-resistant pathogens in blood stream infections associated with hematologic disorders: Five-year single institutional surveillance from 2010 to 2014. Int J Hematol Ther, 3; 1-5, 2017.（京都府立医科大学附属病院感染対策部との共同研究）

Mihara K, Yoshida T, Takei Y, Sasaki N, Takihara Y, Kuroda J, Ichinohe T. T cells bearing anti-CD19- and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells. J Hematol Oncol, 10, 116, 2017.（広島大学原医研血液腫瘍内科部門との共同研究）

Kaneko H, Shimura K, Matsumoto Y, Yoshida M, Taniwaki M, Kuroda J. Alkaline phosphatase flare with hyperostosis of bone metastasis in lung adenocarcinoma treated with gefitinib. J Cancer Metastasis Treat, 3; 34-37, 2017.

Tatekawa S, Chinen Y, Ri M, Narita T, Shimura Y, Matsumura-Kimoto Y, Tsukamoto T, Kobayashi T, Kawata E, Uoshima N, Taki T, Taniwaki M, Handa H, Iida S, Kuroda J. Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signaling axis in multiple myeloma. Br J Haematol, 178;534-546, 2017

Yamasaki S, Suzuki R, Hatano K, Fukushima K, Iida H, Morishima S, Suehiro Y, Fukuda T, Uchida N, Uchiyama H, Ikeda H, Yokota A, Tsukasaki K, Yamaguchi H, Kuroda J, Nakamae H, Adachi Y, Matsuoka K, Nakamura Y, Atsuta Y, Suzumiya J. Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma. Bone Marrow Transplant, 52;969-976,2017.

Kawaji Y, Kaneko H, Fujino T, Kuwahara S, Ohshiro M, Hirakawa Y, Iwai GT, Uchiyama H, Kuroda J, Taniwaki M. Long-term maintenance of hematological and cytogenetic remission in 5q- syndrome after short-term administration of lenalidomide. Indian J Hematol Blood Transfus, 33;443-444,2017.

Ota S, Iwai T, Kawaji Y, Fujino T, Ohshiro M, Hirakawa Y, Chinen Y, Uchiyama H, Kaneko H, Kuroda J. A treatment refractory CD30-positive diffuse large B-cell lymphoma in the ileal neobladder. Ann Hematol, 96;683-684, 2017.

Tsukamoto T, Kiyota M, Kawata E, Uoshima N, Tatekawa S, Chinen Y, Nagoshi H, Mizutani S, Shimura Y, Yamamoto-Sugitani M, Kobayashi T, Horiike S, Yasukawa S, Yanagisawa A, Taniwaki M, Kuroda J. Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era. Int J Hematol, 105;658-667, 2017.

Kanbayashi Y, Matsumoto Y, Kuroda J, Kobayashi T, Horiike S, Hosokawa T, Taniwaki M. Predicting risk factors for varicella zoster virus infection and post herpetic neuralgia after hematopoietic cell transplantation using ordered logistic regression analysis. Ann Hematol, 96: 311-315, 2017.

Kida T, Kohno M, Chinen Y, Tominaga A, Seno T, Tsukamoto T, Kuroda J, Kawahito Y. Intravascular lymphoma in a rheumatoid arthritis patient following short-term methotrexate treatment. Rheumatology, 56;318-320, 2017（京都府立医科大学　免疫内科学教室との共同研究）

Takimoto T, Maegawa S, Tatsumi H, Nagoshi H, Chinen Y, Shimura Y, Kobayashi T, Horiike S, Kiwataki J, Taniwaki M, Kuroda J. Extranodal marginal zone lymphoma of the uterine cervix with concomitant copy number gains of the MALT1 and BCL2 genes. Oncol Lett., 13;3641-3645, 2017

Okuda T, Taki T, Nishida K, Chinen Y, Nagoshi H, Sakakura C, Taniwaki M.　Molecular heterogeneity in the novel fusion gene APIP-FGFR2: Diversity of genomic breakpoints in gastric cancer with high-level amplifications at 11p13 and 10q26.　 Oncol Lett. 2017;13:215-221.

黒田純也. びまん性大細胞型B細胞性リンパ腫の診断と治療の現在と未来. Current status and future perspectives of the diagnosis and treatment of diffuse large B cell lymphoma. 京都府立医科大学雑誌126(11), 737-747, 2017.

古林　勉、黒田純也. 再発・難治多発性骨髄腫（RRMM）の治療戦略－どう使い分けるか－ 2) Patient risk categoryによる使い分け．血液フロンティア「特集：多発性骨髄腫治療の最前線 2017」、27(9), 1277-1284, 2017.

河田英里、黒田純也. 形質細胞性腫瘍の分類と治療開始のタイミング～みんなすぐに治療が必要なの？～ 臨床雑誌「内科」120(4)、853-858, 2017.

黒田純也、前川紗央梨. 再発・難治多発性骨髄腫の治療戦略2017. 血液内科 75(4)、425-430, 2017.

黒田純也. 免疫調節薬の作用機序と骨髄腫治療における役割. BIO Clinica. 32(9), 865-868, 2017.

黒田純也. 再発・難治性多発性骨髄腫に対する治療の考え方と実際．Therapeutic approach for relapsed/refractory multiple myeloma; The logic and practice. 臨床血液 第79回日本血液学会学術集会教育講演特集号. 58(10), 2058-2066, 2017.

黒田純也、志村勇司. 移植非適応多発性骨髄腫に対する初回治療戦略におけるプロテアソーム阻害剤. First line treatment incorporating a proteasome inhibitor for transplant-ineligible multiple myeloma. 臨床血液 58, 999-1005, 2017.

黒田純也、知念良顕. 多発性骨髄腫 -病態解明の進歩と治療の現在- Multiple myeloma: Pathophysiology and progress in management. 臨床血液 58, 487-497, 2017.

名越久朗、黒田純也. 多発性骨髄腫に対する新たな分子標的治療．血液内科. 74(2), 191-195, 2017

志村勇司、黒田純也. 多発性骨髄腫の病態メカニズムと治療標的を整理する. 多発性骨髄腫　新規治療薬の使い方・考え方. 19-24, 先端医学社、東京. 2017.

黒田純也、名越久朗. 骨髄腫の進行をもたらす骨髄腫細胞の分子病態. 生存・増殖シグナル. 多発性骨髄腫Updating 第10巻. 127-136, 医薬ジャーナル社、大阪. 2017.

山田一人、小菅敏幸、岡本和真、小西博貴、塩崎敦、藤原斉、森村玲、村山康利、栗生宜明、生駒久視、中西正芳、黒田純也、岸本光夫、小西英一、大辻英吾. 悪性リンパ腫との鑑別が困難であったリンパ球浸潤胃癌の1切除例. 癌と化学療法 44(12), 1299–1301, 2017.

2016

Tatekawa S, Kohno A, Ozeki K, Watamoto K, Ueda N, Yamaguchi Y, Kobayashi T, Yokota I, Teramukai S, Taniwaki M, Kuroda J, Morishita Y. A novel diagnostic and prognostic biomarker panel for endothelial cell damage-related complications in allogeneic transplantation. Biol Blood Marrow Transplantation, 22; 1573-1581, 2016.

Mizuno Y, Shimura Y, Horiike S, Takimoto T, Maegawa S, Tanba K, Matsumura-Kimoto Y, Sumida Y, Tatekawa S, Tsukamoto T, Chinen Y, Mizutani S, Nagoshi H, Yamamoto-Sugitani M, Matsumoto Y, Kobayashi T, Kuroda J, Taniwaki M. Burkitt lymphoma preceded by autoimmune hemolytic anemia due to anti-D antibody. Intern Med, 55; 2253-2258, 2016.

Mizutani S, Kuroda J, Sasaki N, Kiyota M, Tatekawa S, Tsukamoto T, Maegawa S, Chinen Y, Shimura Y, Nagoshi H, Kobayashi T, Horiike S, Tando S, Fushiki S, Taniwaki M. Quadruple cancers of non-producing multiple myeloma, cholangiocellular carcinoma, and two different thyroid cancers. Intern Med, 55; 1183-1186, 2016.

Ogura M, Ishizawa K, Maruyama D, Uike N, Ando K, Izutsu K, Terui Y, Imaizumi Y, Tsukasaki K, Suzuki K, Izumi T, Usuki K, Kinoshita T, Taniwaki M, Uoshima N, Suzumiya J, Kurosawa M, Nagai H, Uchida T, Fukuhara N, Choi I, Ohmachi K, Yamamoto G, Tobinai K; Japanese Bendamustine Lymphoma Study Group..　Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.　Int J Hematol. 105;470-477, 2016.（多施設共同研究）

Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults.　Nat Genet. 2016;48:569-74.（多施設共同研究）

Miyamura K, Miyamoto T, Tanimoto M, Yamamoto K, Kimura S, Kawaguchi T, Matsumura I, Hata T, Tsurumi H, Saito S, Hino M, Tadokoro S, Meguro K, Hyodo H, Yamamoto M, Kubo K, Tsukada J, Kondo M, Aoki M, Okada H, Yanada M, Ohyashiki K, Taniwaki M.　Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy.　　 Leuk Res. 2016;51:11-18.（多施設共同研究）

Iida S, Tobinai K, Taniwaki M, Shumiya Y, Nakamura T, Chou T.　Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma. Int J Hematol. 2016;104(5):596-604.（多施設共同研究）

Igarashi T, Ogura M, Itoh K, Taniwaki M, Ando K, Kuroda Y, Yamamoto K, Uike N, Tomita A, Nagai H, Kurosawa M, Mori S, Nawano S, Terauchi T, Ohashi Y, Tobinai K 　Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden.　Int J Hematol. 2016;104:700-708.（多施設共同研究）

Iida S, Ogiya D, Abe Y, Taniwaki M, Asou H, Maeda K, Uenaka K, Nagaoka S, Ishiki T, Conti I, Tobinai K．Dose-escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma.　Cancer Sci. 2016;107:1281-9.（多施設共同研究）

Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet. 2016 Mar 28.(多施設共同研究）

Watanabe T, Tobinai K, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Kashihara T, Iida S. A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma. Br J Haematol. 2016 Mar;172(5):745-56.（多施設共同研究）

Tanba K, Uoshima N, Uchiyama H, Kawata E, Isa R, Yamaguchi J, Tsutsumi Y, Akaogi T, Kobayashi Y, Katsura K, Kuroda J, Taniwaki M. Toxic epidermal necrolysis in adult T cell leukemia/lymphoma treated with mogamulizumab. Ann Hematol. 2016 Mar;95(4):661-2.

Suzuki K, Shinagawa A, Uchida T, Taniwaki M, Hirata H, Ishizawa K, Matsue K, Ogawa Y, Shimizu T, Otsuka M, Matsumoto M, Iida S, Terui Y, Matsumura I, Ikeda T, Takezako N, Ogaki Y, Midorikawa S, Houck V, Ervin-Haynes A, Chou T. Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: a phase II study. Cancer Sci. 2016 Feb 23.（多施設共同研究）

Kobayashi T, Kuroda J, Yokota I, Tanba K, Fujino T, Kuwahara S, Isa R, Yamaguchi J, Kawata E, Akaogi T, Uchiyama H, Kaneko H, Uoshima N, Kobayashi Y, Teramukai S, Taniwaki M. The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era. Blood Cancer J. 2016 Jan 15;6:e383.（京都府立医科大学血液・腫瘍内科と関連施設の共同研究）

Takimoto T, Nakao M, Nakajo T, Chinen Y, Kuroda J, Taniwaki M. Acute myocardial infarction as the initial thrombotic event of thrombotic thrombocytopenic purpura. Blood Coagul Fibrinolysis. 2016 Jan 11.

Okabe M, Yamaguchi H, Usuki K, Kobayashi Y, Kawata E, Kuroda J, Kimura S, Tajika K, Gomi S, Arima N, Mori S, Ito S, Koizumi M, Ito Y, Wakita S, Arai K, Kitano T, Kosaka F, Dan K, Inokuchi K. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. Leuk Res. 2016 Jan;40:68-76.(多施設共同研究）

扇谷大輔、柴山浩彦、中谷英仁、安藤　潔、鈴木憲史、黒田芳明、内田俊樹、丸山　大、松本守生、末永孝生、飯田真介、照井康仁、李　政樹、張　高明、青墳　伸之、田端淑恵、小西　順、大橋一輝、品川篤司、杉浦　勇、黒田純也、宮本敏浩、小椋美知則、飛内賢正、金倉　譲、堀田知光. 移植非適応の多発性骨髄腫日本人患者に対するMPB療法（JPN-102試験）の長期フォローアップ解析. 臨床血液 57, 2311-2318, 2016

名越久朗、水野芳美、黒田純也. セザリー症候群における造血幹細胞移植. 日本臨床74巻増刊号10「白血病学（下）」．286-291, 2016.

杉谷未央、丹波和奈、黒田純也. ガレクチン3によるCMLの薬剤抵抗性獲得と骨髄棲息性促進. 本臨床74巻増刊号10「白血病学（下）」．508-513, 2016.

黒田純也. グアデシタビン(SGI-110)による急性骨髄性白血病、ならびに骨髄異形成症候群の治療. 本臨床74巻増刊号10「白血病学（下）」．514-518, 2016.

小杉智、柴山浩彦、木田亨、中谷英仁、太田健介、金子仁臣、八木秀男、田中宏和、淵田真一、中谷 綾、小林正行, 黒田純也、上辻由里、魚嶋伸彦、足立陽子、通堂 満、島崎千尋、野村昌作、日野雅之、松村 到、谷脇雅史、金倉譲、高折晃史. 骨髄腫関連疾患における二次癌の検討： 関西骨髄腫フォーラムデータベースを用いた解析. 臨床血液、57, 839-947, 2016.

黒田純也、立川章太郎. RSK2、PDPK1を標的とした骨髄腫治療開発. 日本臨床74巻増刊号5「多発性骨髄腫学」．180-184, 2016.

黒田純也、水谷信介. ポマリドマイド. 日本臨床74巻増刊号5「多発性骨髄腫学」．330-334, 2016.

黒田純也. 多発性骨髄腫の遺伝子異常と細胞シグナル異常. 造血器腫瘍アトラス.（改訂第5版）（谷脇雅史、横田昇平、黒田純也 編）、日本医事新報社、東京、370-375, 2016.

黒田純也. 多発性骨髄腫に対する新規抗体療法. 造血器腫瘍アトラス.（改訂第5版）（谷脇雅史、横田昇平、黒田純也 編）、日本医事新報社、東京、763-769, 2016.